Table 2.

Solubilization of CYP27A1 and CYP46A1^a

	Protein (pmol/mg tissue protein)
	Total membrane pellet
Protein/Peptide	without treatment	1% sodium cholate		8 M urea		1% SDS
		supernatant	pellet	supernatant	pellet	supernatant	pellet
CYP27A1
LYPVVPTNSR	0.19 ± 0.04	0.06 ± 0.01	0.14 ± 0.02	0.12 ± 0.02	0.07 ± 0.01	0.19 ± 0.03	ND
IQHPFGSVPFGYGVR	0.15 ± 0.03	0.05 ± 0.01	0.10 ± 0.02	0.10 ± 0.02	0.06 ± 0.01	0.15 ± 0.03	ND
consensus	0.17 ± 0.04 (100%)	0.06 ± 0.01 (35%)	0.12 ± 0.02 (71%)	0.11 ± 0.02 (65%)	0.07 ± 0.01 (41%)	0.17 ± 0.03 (100%)	-
CYP46A1
LLEEETLIDFVR	0.39 ± 0.07	ND	0.42 ± 0.07	0.19 ± 0.03	0.20 ± 0.03	0.37 ± 0.07	ND
VIDLAFSR	0.39 ± 0.06	ND	0.38 ± 0.07	0.19 ± 0.03	0.22 ± 0.03	0.40 ± 0.07	ND
consensus	0.39 ± 0.08 (100%)	-	0.40 ± 0.08 (103%)	0.19 ± 0.04 (49%)	0.21 ± 0.04 (53%)	0.39 ± 0.09 (100%)	-

^aMeasurements were performed on the temporal lobe (patient ID 9517, Table S1) total membrane pellet and on the supernatant and pellet fractions of the total membrane pellet generated by centrifugation at 153 000g for 30 min after treatment with various solubilizing agents. The concentration was calculated for three experimental replicates by monitoring three transitions per individual peptide and presented as mean ± SD. The monitored transitions are summarized in the Supporting Information (Table S2). For the consensus, the data for two peptides from CYP27A1 or CYP46A1 were combined and presented as mean ± SD. For comparison, the concentrations in the total membrane pellet were taken as a 100%, and the other concentrations were presented as a percentile of the concentration in the total membrane pellet. ND, not detected.